Skip to content

Changes in bone width with injectable blood cell rich protein and patients tooth graft prepared by new versus conventional protocol

Horizontal ridge augmentation using autologous partially demineralized dentinal blocks prepared with novel versus conventional injectable platelet rich fibrin protocol a randomized clinical trial - NILL

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/086517
Enrollment
24
Registered
2025-05-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K063- Horizontal alveolar bone loss

Interventions

Intervention1: Novel injectable Platelet Rich Fibrin with autologous Partially Demineralized Dentinal Graft duration six months : Teeth indicated for extraction will be extracted under local anaesthes

Sponsors

Sagaya Cyril Stegy S
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Horizontal ridge defect Seibert class one Systematically healthy individuals older than eighteen years of age with good oral hygiene and plaque index lesser than fifteen percent Patients requiring at least one single rooted tooth extraction with periodontally healthy adjacent teeth Teeth that would require extraction if they were non restorable due to tooth fracture unfavorable crown root ratio and extensive caries

Exclusion criteria

Exclusion criteria: Smokers Known allergy and systemic conditions that may compromise healing or bone mechanism Having a history of radiotherapy chemo therapy or bisphosphonate therapy Females who are pregnant or lactating Patients with poor oral hygiene

Design outcomes

Primary

MeasureTime frame
To evaluate the changes in bone width between ridge augmented with PDDM and novel injectable PRF protocol versus PDDM with conventional injectable PRF protocol using CBCT analysis at preoperative, immediate postoperative and six months Timepoint: six months

Secondary

MeasureTime frame
To evaluate clinical parameters like pain swelling infection and inflammation between conventional and novel protocol at 1 7 14 days Timepoint: 1 7 14 days;To evaluate the histopathological findings like the percentage of new bone, residual graft material and signs of inflammation at 6 months Timepoint: 6 months

Countries

India

Contacts

Public ContactEazhil Raj

Chettinad Dental College and Research Institute

dreazhilcdcri@gmail.com9841332224

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026